Document is current
Any future updates will be listed below
-
Authors
Traboulsi, Wael
Gaur, Pankaj https://orcid.org/0000-0002-9718-3565
Kundu, Subhadip
Ramlaoui, Zainab
Priestley-Milianta, Christopher https://orcid.org/0000-0002-5030-3750
Iyengar, Aishwariya
Shobaki, Nour https://orcid.org/0000-0001-9073-0987
Sarhan, Dareen
Lee, Min-Jung
Lee, Jung-Min
Pavlakis, George N.
Mkrtichyan, Mikayel
Valge-Archer, Viia E.
Barry, Simon T. https://orcid.org/0000-0002-8511-0588
Verma, Vivek https://orcid.org/0000-0001-8129-4140
Gupta, Seema https://orcid.org/0000-0003-0106-595X
Khleif, Samir N. https://orcid.org/0000-0003-2707-5224
- License Information
-
More Information
Article History
Received: 16 June 2025
Accepted: 26 November 2025
First Online: 12 January 2026
Competing interests
: S.N.K., S.G. and W.T. are inventors on patent applications (US Patent application no. PCT/US2024/024381) related to work on the methods for producing a super-central memory CD8 + T cell subtype by PARP inhibition and uses thereof. S.N.K. is a founder of Georgiamune and Precision Immunotherapeutics; a consultant or a member of the Board Georgiamune and Emerald; and a member of the Advisory Board of Nectin Therapeutics, Northwest Biotherapeutics, Stemline Therapeutics and UAMS Winthrop P. Rockefeller Cancer Institute; has research support from AstraZeneca, Bristol Myers Squibb, Johnson & Johnson and Merck; has equity (options) in Ayala (formerly Advaxis), IO Biotechnology, KAHR Medical, Nectin Therapeutics, Northwest Biotherapeutics, PDS Biotechnology and SandboxAQ. V.E.V.-A. and S.T.B. are employees and shareholders of AstraZeneca. The other authors declare no competing interests.
